TP53 and metastatic melanoma: The TP53 mutation had previously been considered a potential negative predictor of metastatic melanoma treated with CTLA-4 blockade (Xiao et al., 2018), while a very recent paper showed that cell cycle regulators, such as TP53 and CDKN2A, do not appear to significantly alter clinical outcomes when immune checkpoint inhibitors are used (DeLeon et al., 2020).